20-24 September.

Bayer HealthCare to provide its clinical trial data in a joint Multidisciplinary Congress Bayer Health care today announced that data from a lot more than 30 clinical trials evaluating 3 products in the business’s oncology portfolio – Nexavar tablets, regorafenib and Alpharadin – will end up being presented in the joint 15th European Cancer tumor Organisation and 34th European Culture for Medical Oncology Multidisciplinary Congress, 20-24 September, 2009 in Berlin, Germany. ‘Bayer is focused on finding and developing innovative cancer-fighting therapies, and as a worldwide organization with widespread effect and reach, we’re able to apply our experience, understanding and passion to provide treatments that could make lifestyle better for cancer sufferers across the globe,’ said Rob Rosen, Mind of the Therapeutic Region Oncology at Bayer Health care. ‘While much improvement has been manufactured in the treating cancer, there continues to be an unmet medical dependence on improved therapies that might help individuals manage their disease, dealing with cancer tumor as a chronic disease ultimately, rather than devastating disease orlistatindia.com here .’ Nexavar Data Highlights Nexavar happens to be approved in a lot more than 80 countries for the treating individuals with hepatocellular carcinoma , or liver malignancy, and in a lot more than 90 countries for the treating individuals with advanced renal cell carcinoma , or kidney cancer.

More than 13 Currently,000 people function for the Bayer Group in China, which can be among the main focusses of the business’s global expenditure. About Bayer Health care The Bayer Group is usually a worldwide enterprise with primary competencies in the areas of healthcare, agriculture and high-tech components. Bayer Health care, a subgroup of Bayer AG with annual product sales of EUR 18.9 billion , is among the world’s leading, innovative companies in the healthcare and medical items industry and is situated in Leverkusen, Germany. The ongoing firm combines the global actions of the pet Health, Consumer Care, HEALTH CARE and Pharmaceuticals divisions.